Professor Gerald Watts

Professor Gerald Watts

University of Western Australia, Perth (Australia)

GERALD F WATTS, DSc DM PhD FRCP FRACP FCSANZ. Gerald Watts trained at Imperial & King’s College, London University, and was a scholar at Wolfson College, Oxford University. He is a senior consultant physician, specializing in the rapidly developing field of cardio-metabolic medicine, and current chair of the Familial Hypercholesterolemia Australasia Network. He leads the Cardio-metabolic Service in the Departments of Cardiology and Internal Medicine at Royal Perth Hospital and is Winthrop Professor of Cardio-metabolic Medicine in the University of Western Australia. Research interests include fundamental and applied aspects of lipid disorders and cardiovascular prevention, and improving healthcare delivery for patients with high risk dyslipidemias, in particular familial hypercholesterolaemia and hyperchylomicronaemia. He has supervised several Masters, MD and PhD students and post-doctoral research fellows, and holds several research grants, with multiple collaborations.

Presentations Articles

A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome

Event: ESC Congress 2024

Topic: Drug therapy

Session: Smaller trials, trial updates, and other studies on lipid therapy

Access

RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session: Nature Medicine: highlights in cardiovascular research

Access

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

Event: ESC Congress 2020

Topic: Lipid-Lowering Agents

Session: Novel Approaches to Lipid Lowering Therapy

Access

Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism: the FLOREY stable isotope study

Event: ESC Congress 2016

Topic: CAD and comorbidities

Session: Comorbidities and risk for CAD

Access

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

Event: ESC Asia with APSC & AFC 2020

Topic: Lipid-Lowering Agents

Session: Abstract Programme

Access

ESC 365 is supported by

Explore sponsored resources

Professor Gerald Watts

Biography

Contributor content

A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome

RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism: the FLOREY stable isotope study

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

ESC 365 is supported by